Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720 - PubMed (original) (raw)
Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720
Takashi Maki et al. Transplantation. 2005.
Abstract
Background: Treatment of nonobese diabetic (NOD) mice with FTY720 before the development of insulitis prevents the onset of diabetes. In this study, the authors investigated whether FTY720 treatment of NOD mice with established insulitis prevents the development of diabetes.
Methods: FTY720 (1 mg/kg) was administered continuously to euglycemic NOD mice starting at 14 or 23 weeks of age. A group of untreated, age-matched NOD mice served as controls. Mice with more than 300 mg/dL blood glucose on three consecutive measurements were considered diabetic.
Results: Diabetes developed in control mice starting at 13 weeks of age and reached 78% by 33 weeks of age. Mice at 14 and 23 weeks of age exhibited extensive insulitis that progressed with age. Continuous oral administration of FTY720 starting at either age completely prevented the development of diabetes. However, its withdrawal at 37 weeks of age led to abrupt diabetes onset. Pancreases of FTY720-treated diabetes-free mice showed peripheral insulitis, with strong insulin staining. The protection from diabetes was also achieved by intraperitoneal injection of FTY720 or sirolimus (1.5 mg/kg). Unlike FTY720, withdrawal of sirolimus did not induce diabetes. Continuous oral FTY720 (3 mg/kg) treatment in overtly diabetic NOD mice led to complete reversal of diabetes in 6 of 11 mice. The standard adoptive transfer study in NOD-severe combined immunodeficient mice showed that peripheral lymphoid organs of FTY720-treated mice contained diabetogenic cells but not dominant immunoregulatory cells.
Conclusions: FTY720, which does not cause generalized immunosuppression, may be a safe and benign therapeutic agent for chronic use to prevent or cure type 1 diabetes.
Similar articles
- Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice.
Maki T, Gottschalk R, Monaco AP. Maki T, et al. Transplantation. 2002 Dec 27;74(12):1684-6. doi: 10.1097/00007890-200212270-00006. Transplantation. 2002. PMID: 12499880 - Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells.
Morris MA, McDuffie M, Nadler JL, Ley K. Morris MA, et al. Autoimmunity. 2011 Mar;44(2):115-28. doi: 10.3109/08916934.2010.499885. Epub 2010 Aug 9. Autoimmunity. 2011. PMID: 20695767 Free PMC article. - Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Penaranda C, et al. Diabetes. 2010 Jun;59(6):1461-8. doi: 10.2337/db09-1129. Epub 2010 Mar 18. Diabetes. 2010. PMID: 20299465 Free PMC article. - [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Klatt J, Hartung HP, Hohlfeld R. Klatt J, et al. Nervenarzt. 2007 Oct;78(10):1200-8. doi: 10.1007/s00115-007-2298-9. Nervenarzt. 2007. PMID: 17668161 Review. German. - FTY720: mechanism of action and potential benefit in organ transplantation.
Brinkmann V. Brinkmann V. Yonsei Med J. 2004 Dec 31;45(6):991-7. doi: 10.3349/ymj.2004.45.6.991. Yonsei Med J. 2004. PMID: 15627289 Review.
Cited by
- The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.
Davoodi-Semiromi A, Wasserfall CH, Xia CQ, Cooper-DeHoff RM, Wabitsch M, Clare-Salzler M, Atkinson M. Davoodi-Semiromi A, et al. PLoS One. 2012;7(5):e36079. doi: 10.1371/journal.pone.0036079. Epub 2012 May 14. PLoS One. 2012. PMID: 22615750 Free PMC article. - Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
Behrangi N, Fischbach F, Kipp M. Behrangi N, et al. Cells. 2019 Jan 7;8(1):24. doi: 10.3390/cells8010024. Cells. 2019. PMID: 30621015 Free PMC article. Review. - Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.
Bajwa A, Jo SK, Ye H, Huang L, Dondeti KR, Rosin DL, Haase VH, Macdonald TL, Lynch KR, Okusa MD. Bajwa A, et al. J Am Soc Nephrol. 2010 Jun;21(6):955-65. doi: 10.1681/ASN.2009060662. Epub 2010 Mar 25. J Am Soc Nephrol. 2010. PMID: 20338995 Free PMC article. - Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells.
Imasawa T, Koike K, Ishii I, Chun J, Yatomi Y. Imasawa T, et al. Biochem Biophys Res Commun. 2010 Feb 5;392(2):207-11. doi: 10.1016/j.bbrc.2010.01.016. Epub 2010 Jan 12. Biochem Biophys Res Commun. 2010. PMID: 20060809 Free PMC article. - Future Perspective of Diabetic Animal Models.
Pandey S, Dvorakova MC. Pandey S, et al. Endocr Metab Immune Disord Drug Targets. 2020;20(1):25-38. doi: 10.2174/1871530319666190626143832. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31241444 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical